AVEO Oncology Announces Participation at the 11th Annual SVB Leerink Global Healthcare Conference
AVEO Oncology (Nasdaq: AVEO) will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 9:20 a.m. ET. A live webcast of the discussion will be available in the investors section of AVEO’s website, with an archive accessible for 30 days post-event. AVEO is focused on oncology, marketing FOTIVDA® for treating relapsed or refractory renal cell carcinoma (RCC). The company is also exploring new immuno-oncology combinations and other clinical development programs.
- AVEO is actively participating in industry conferences to engage with investors.
- FOTIVDA® is currently marketed in the U.S. for treating RCC, showcasing commercial viability.
- AVEO is exploring combinations of FOTIVDA in immuno-oncology, potentially expanding its market applications.
- None.
BOSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 9:20 a.m. eastern time.
A live webcast of the fireside chat can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.
About AVEO Pharmaceuticals, Inc.
AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the United States for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Actual results or events could differ materially due to a number of important factors, including risks discussed in the sections titled “Risk Factor Summary,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources” included in AVEO’s most recent Annual Report on Form 10-K, its quarterly reports on Form 10-Q and in other filings that AVEO makes with the SEC. The forward-looking statements in this press release represent AVEO’s views as of the date of this press release. AVEO anticipates that subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO’s views as of any date other than the date of this press release.
AVEO:
Hans Vitzthum
LifeSci Advisors, LLC
Hans@LifeSciAdvisors.com
(617) 430-7578
Source: AVEO Oncology
FAQ
When is the AVEO fireside chat at the SVB Leerink Global Healthcare Conference?
How can I access the AVEO fireside chat?
What is FOTIVDA and what conditions does it treat?
Is AVEO involved in any other drug development?
